ASH 2018 | Impact of MRD on FLT3-ITD AML

Mark Levis

The predictive role of measurable residual disease (MRD) on survival across the hematology-oncology space is under intense investigation. Here, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the impact of MRD on FLT3-ITD acute myeloid leukemia (AML). Dr Levis highlights how measuring MRD, using an NGS-based assay, revealed a potential association between MRD negativity and longer survival in patients with relapsed/refractory FLT3-ITD AML. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video